Revance Therapeutics, Inc. Class Action Lawsuit - RVNC

Company
Revance Therapeutics, Inc. (NASDAQ: RVNC)
Lead Plaintiff Deadline
February 8, 2022 (Expired)
Class Period
November 25, 2019 - October 11, 2021

Expired

Lead Plaintiff Deadline

Feb 8, 2022

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

(i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be eligible to join the RVNC class action lawsuit, you must have incurred a loss on shares of Revance purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Revance during the relevant time frame or pursuant to the relevant offering(s), you have until February 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

TOP